Translational Neural Devices (R61/R33 - Clinical Trial Optional)

US · MD National Institutes of Health (NIH) grant open #PAR-25-053

Response due Jan 28, 2027 · 00:00 UTC

Summary

The National Institutes of Health (NIH) is soliciting applications under Program Announcement PAR-25-053 for the Translational Neural Devices funding opportunity. This R61/R33 phased award mechanism supports the development and translation of neural devices from early-stage research through more advanced translational milestones. Clinical trials are optional under this announcement. The opportunity is open for an extended period from late 2024 through early 2027.

What they want

Technical requirements

R61/R33 phased award mechanism required
Clinical trial component is optional but must be declared at time of application
Applications must align with translational neural device development objectives

How they evaluate

Submission: Grants.gov federal grants portal (electronic submission)

Risks & flags

Extremely long open window (over 2 years) is typical for NIH Program Announcements but may limit urgency signals
Minimal detail provided in the synopsis — full funding opportunity announcement (FOA) required to assess true scope and eligibility constraints

Market context

inferred from NAICS

R&D in Physical, Engineering, Life Sciences (except Nanotech & Biotech)

NAICS 541715

US market size: $95B
Typical award: $100K – $50M+

Typical buyers

DoDNSFNIHNASADOE

Commonly required

DCAA-compliant accountingITARCMMC L2

Translational Neural Devices (R61/R33 - Cl…

Due Jan 28

Onboard ↗